It was a pleasure to meet with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the emerging therapies for drug-resistant tuberculosis.
The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Question:
- What are the most promising emerging therapies in tuberculosis treatment? (0:25)
Disclosures: Kelly Dooley has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ECCMID, Virtual 2021
